Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
BackgroundTreatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broa...
Guardado en:
Autores principales: | Camilla M. Grunewald, Corinna Haist, Carolin König, Patrick Petzsch, Arthur Bister, Elfriede Nößner, Constanze Wiek, Kathrin Scheckenbach, Karl Köhrer, Günter Niegisch, Helmut Hanenberg, Michèle J. Hoffmann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e19 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells
por: Arthur Bister, et al.
Publicado: (2021) -
Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy
por: Luis Felipe Olguín-Contreras, et al.
Publicado: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover M, et al.
Publicado: (2021) -
Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
por: Alireza Rajabzadeh, et al.
Publicado: (2021) -
Adoptive chimeric antigen receptor T cell (CAR-T) and Treg cell-based immunotherapies: Frontier therapeutic aspects in cancers
por: Mehran Bahraini, et al.
Publicado: (2021)